HitGen has entered into a drug discovery research collaboration with Gilead Sciences to identify potential small molecule leads against targets of interest to Gilead. In this collaboration, HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment and will be eligible for milestone payments from Gilead.
“We are delighted to enter this collaboration with Gilead, an industry leader in pharmaceutical research and development. We believe the collaboration reinforces the role and reputation of HitGen’s platform in the rapidly developing field of DNA-encoded chemistry. We will work closely with Gilead scientists to generate new small-molecule lead compounds for their research programs to help bring transformative medicines to patients,” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen.